RESUMEN
BACKGROUND: Giant cell tumor of bone (GCTB) is a locally aggressive neoplasm with a high propensity for recurrence following intralesional curettage. The introduction of denosumab, a RANKL inhibitor, has shown potential in facilitating joint-sparing surgery. However, concerns exist regarding its impact on local recurrence rates. This study aimed to evaluate the efficacy and safety of combined preoperative denosumab with adjuvant microwave ablation (MWA) for the treatment of high-risk GCTB. METHODS: We conducted a retrospective review of 19 patients with high-risk GCTB who underwent preoperative denosumab treatment followed by curettage and adjuvant MWA. The primary outcome measure was the local recurrence rate, with secondary outcomes including functional status assessed by the Musculoskeletal Tumor Society (MSTS) score and safety profile of the treatment. RESULTS: In this retrospective analysis, we evaluated the outcomes of 19 patients with high-risk GCTB treated with preoperative denosumab and adjuvant MWA. The median follow-up duration was 33.1 months, 3 patients (15.8%) experienced local recurrence at a median of 21.6 months postoperatively and the local recurrence-free survival was 81.2% at two years. Notably, no patient developed lung metastasis, and all recurrences were successfully managed with repeat curettage and MWA, with a mean MSTS score of 27.3. No patient required joint replacement due to tumor recurrence, resulting in a 100% joint preservation rate. CONCLUSION: The combination of preoperative denosumab and adjuvant MWA is a feasible and effective strategy for the management of high-risk GCTB, providing effective local control with preserved joint function. This approach may offer a surgical alternative for young patients where joint preservation is paramount.
Asunto(s)
Neoplasias Óseas , Denosumab , Tumor Óseo de Células Gigantes , Microondas , Humanos , Denosumab/uso terapéutico , Estudios Retrospectivos , Femenino , Masculino , Adulto , Microondas/uso terapéutico , Tumor Óseo de Células Gigantes/cirugía , Tumor Óseo de Células Gigantes/tratamiento farmacológico , Neoplasias Óseas/cirugía , Neoplasias Óseas/tratamiento farmacológico , Persona de Mediana Edad , Adulto Joven , Resultado del Tratamiento , Terapia Combinada , Recurrencia Local de Neoplasia , Adolescente , Conservadores de la Densidad Ósea/uso terapéutico , Estudios de Seguimiento , Legrado/métodos , Cuidados Preoperatorios/métodosRESUMEN
BACKGROUND: The Musculoskeletal Tumor Society Score (MSTS) is widely used to evaluate functioning following surgery for bone and soft-tissue sarcoma. However, concerns have been raised about its content validity due to the lack of patient involvement during item development. Additionally, literature reports inconsistent results regarding data quality and structural validity. This study aimed to evaluate content, structural and construct validity of the Danish version of the MSTS for lower extremity (MSTS-LE). METHODS: The study included patients from three complete cohorts (n = 87) with bone sarcoma or giant cell tumour of bone who underwent bone resection and reconstruction surgery in hip and knee. Content validity was evaluated by linking MSTS items to frameworks of functioning, core outcome sets and semi-structured interviews. Data quality, internal consistency and factor analysis were used to assess the underlying structure of the MSTS. Construct validity was based on predefined hypotheses of correlation between the MSTS and concurrent measurements. RESULTS: Content validity analysis revealed concerns regarding the MSTS. The MSTS did not sufficiently cover patient-important functions, the item Emotional acceptance could not be linked to the framework of functioning, the items Pain and Emotional acceptance pertained to domains beyond functioning and items' response options did not match items. A two-factor solution emerged, with the items Pain and Emotional acceptance loading highly on a second factor distinct from functioning. Internal consistency and construct validity showed values below accepted levels. CONCLUSION: The Danish MSTS-LE demonstrated inadequate content validity, internal consistency, and construct validity. In addition, our analyses did not support unidimensionality of the MSTS. Consequently, the MSTS-LE is not a simple reflection of the construct of functioning and the interpretation of a sum score is problematic. Clinicians and researcher should exercise caution when relying solely on MSTS scores for assessing lower extremity function. Alternative outcome measurements of functioning should be considered for the evaluation of postoperative function in this patient group.
Asunto(s)
Neoplasias Óseas , Tumor Óseo de Células Gigantes , Procedimientos de Cirugía Plástica , Humanos , Masculino , Femenino , Neoplasias Óseas/cirugía , Neoplasias Óseas/psicología , Adulto , Tumor Óseo de Células Gigantes/cirugía , Tumor Óseo de Células Gigantes/patología , Persona de Mediana Edad , Procedimientos de Cirugía Plástica/métodos , Osteosarcoma/cirugía , Osteosarcoma/psicología , Osteosarcoma/patología , Adulto Joven , Anciano , Extremidad Inferior/cirugía , Encuestas y Cuestionarios , Adolescente , Reproducibilidad de los Resultados , Calidad de Vida , Sarcoma/cirugíaRESUMEN
INTRODUCTION: Giant cell tumors of the bone (GCTB) are aggressive neoplasms, with rare occurrences in the posterior pelvis and sacral area. Surgical challenges in this region include the inability to apply a tourniquet and limited cementation post-curettage due to proximity to neurovascular structures, leading to potential complications. This case-control study explores the impact of preoperative embolization on GCTB located in the iliosacral region. METHODS: Five surgeries (January-December 2021) for pelvic GCTB (3 sacrum, 2 posterior ilium) were performed on four patients. Diagnosis was confirmed through preoperative CT-guided biopsies. One surgery involved curettage with PMMA cement filling, while four surgeries had curettage without cavity filling. Preoperative embolization of the tumor feeding vessel occurred approximately 16 h before surgery in two cases. Denosumab treatment was not administered. RESULTS: Tumor volume, assessed by preoperative MRI, was comparable between patients with and without preoperative embolization (p = .14). Surgeries without embolization had a mean intraoperative blood loss of 3250 ml, erythrocyte transfusion volume of 1125 ml, and a mean surgical time of 114.5 min for two surgeries. Surgeries with preoperative embolization showed a mean intraoperative blood loss of 1850 ml, no erythrocyte transfusion requirement, and a mean surgical time of 68 min. CONCLUSION: Curettage of GCTB in the posterior pelvis and sacrum presents challenges, with significant intraoperative blood loss impacting surgical time and transfusion needs. Preoperative embolization may be beneficial in reducing blood loss during surgery in these cases.
Asunto(s)
Neoplasias Óseas , Embolización Terapéutica , Tumor Óseo de Células Gigantes , Cuidados Preoperatorios , Sacro , Humanos , Embolización Terapéutica/métodos , Tumor Óseo de Células Gigantes/patología , Tumor Óseo de Células Gigantes/cirugía , Tumor Óseo de Células Gigantes/terapia , Neoplasias Óseas/patología , Neoplasias Óseas/cirugía , Neoplasias Óseas/terapia , Femenino , Adulto , Estudios de Casos y Controles , Masculino , Sacro/cirugía , Sacro/patología , Ilion/patología , Persona de Mediana Edad , Estudios de Seguimiento , Pronóstico , Adulto Joven , Huesos Pélvicos/patología , Huesos Pélvicos/cirugía , Legrado/métodosRESUMEN
We present a case detailing the diagnosis and management of a periprosthetic giant cell tumour in a female patient in her 70s, who had undergone total knee arthroplasty (TKA) for primary osteoarthritis in her right knee 7 years prior. The patient reported 4 months of painful weight-bearing. Various imaging modalities, including plain radiographs, CT scans and MRI, revealed a sizeable lytic lesion beneath the TKA prosthesis, along with loosening of the tibial component.Blood tests and analyses of synovial fluid ruled out periprosthetic joint infection, and a biopsy confirmed the diagnosis of a giant cell tumour of the bone. Treatment entailed en bloc resection of the tumour and revision of the TKA using a hinged, oncological-type megaprosthesis. Surgical procedures involved careful resection of the proximal tibia, preservation of vasculature and the creation of a medial gastrocnemius muscle flap. Following surgery, the patient underwent supervised rehabilitation with a functional brace.
Asunto(s)
Artroplastia de Reemplazo de Rodilla , Neoplasias Óseas , Tumor Óseo de Células Gigantes , Prótesis de la Rodilla , Reoperación , Tibia , Humanos , Femenino , Tibia/cirugía , Tibia/patología , Tibia/diagnóstico por imagen , Artroplastia de Reemplazo de Rodilla/métodos , Tumor Óseo de Células Gigantes/cirugía , Tumor Óseo de Células Gigantes/patología , Tumor Óseo de Células Gigantes/diagnóstico por imagen , Neoplasias Óseas/cirugía , Neoplasias Óseas/patología , Anciano , Falla de PrótesisRESUMEN
El tumor de células gigantes (TCG) constituye un tumor óseo benigno relativamente frecuente. Se caracteriza por ser localmente agresivo y el lugar de presentación más frecuente es a nivel del esqueleto axial (fémur distal o tibia proximal). Hasta la actualidad, existen escasos informes de presentaciones atípicas, como a nivel del esternón. En este informe, se presenta el caso de una paciente mujer de 24 años que presenta tumoración indurada a nivel de la región esternal de crecimiento progresivo asociado a dolor. Los hallazgos radiológicos revelan tumoración osteolítica que tiene como origen el cuerpo del esternón y lo compromete casi en su totalidad. Este se proyecta hacia las partes blandas y llega al plano superficial. Debido a la extensión de la enfermedad y al compromiso extenso en el cuerpo del esternón, se realiza la resección del cuerpo y manubrio esternal. El defecto es reconstruido con malla de polipropileno, barras de titanio, parche de epiplón y autoinjerto de piel; se obtiene una adecuada estabilidad de la caja torácica y resultados estéticos favorables. El caso tiene un adecuado manejo oncológico puesto que la resección es completa con márgenes microscópicos libres (resección R0).
Giant cell tumor (GCT) constitutes a relatively common benign bone tumor, characteri-zed by its local aggressiveness. The most frequent site of occurrence is in the axial ske-leton (distal femur or proximal tibia). To date, there have been few reports of atypical presentations, such as at the level of the sternum. In this report, we present the case of a 24-year-old female patient who presented with an indurated mass in the sternal region, progressively growing and associated with pain. Radiological findings revealed an osteolytic mass originating from the body of the sternum, involving almost its entire extent and projecting into the soft tissues, reaching the superficial plane. Due to the extent of the disease and the extensive involvement of the sternal body, resection of the body and manubrium of the sternum was performed. The surgical defect was reconstructed with polypropylene mesh, titanium bars, an omental patch and a skin graft, achieving adequate stability of the thoracic cage and favorable cosmetic results.
Asunto(s)
Humanos , Femenino , Adulto , Polipropilenos , Tumor Óseo de Células Gigantes/cirugía , Neoplasias/diagnóstico , Perú , Prótesis e Implantes , Esternón/cirugía , Trasplante Autólogo , Biopsia , Tomografía , Diagnóstico DiferencialRESUMEN
SummaryGiant cell tumours of bone are benign and locally aggressive tumours that usually occur in young adults and at the epiphysial locations after physeal closure. Occurrence outside of epiphysial locations and appearance in geriatric patients is rare. We report a case of a woman in her late 60s with a giant cell tumour of the mid-shaft of the right tibia. Extended curettage and biological reconstruction were performed with autologous double-barrel fibular struts and tri-cortical iliac crest bone grafting. At the 28-month follow-up examination, we noted full bony union at both ends with successful consolidation of the fibular struts, and importantly, no evidence of recurrence or other complications was observed.
Asunto(s)
Neoplasias Óseas , Tumor Óseo de Células Gigantes , Tibia , Humanos , Femenino , Tibia/diagnóstico por imagen , Tibia/cirugía , Tibia/patología , Neoplasias Óseas/cirugía , Neoplasias Óseas/patología , Neoplasias Óseas/diagnóstico por imagen , Tumor Óseo de Células Gigantes/cirugía , Tumor Óseo de Células Gigantes/patología , Tumor Óseo de Células Gigantes/diagnóstico por imagen , Legrado , Trasplante Óseo/métodos , Persona de Mediana Edad , Ilion/diagnóstico por imagen , Peroné/diagnóstico por imagen , Peroné/patología , Peroné/cirugía , Diáfisis/cirugía , Resultado del TratamientoRESUMEN
BACKGROUND: The ideal treatment for giant cell tumor of bone (GCTB) is still controversial. Various surgical adjuvants have been introduced following intralesional curettage to improve local control rates. However, findings from relevant studies are inconsistent, and no consensus has been reached. The purpose of this study is to determine what intraoperative adjuvant is effective in decreasing the recurrence of GCTB. METHODS: We performed a systematic review and meta-analysis of articles published in the PubMed and Embase electronic databases which assessed the recurrence rate of GCTB following intralesional curettage with or without various surgical adjuvants. Two authors independently evaluated all publications. Meta-analysis was performed with Stata/MP (Version 17.0, StataCorp LLC, TX, USA) and Review Manager (RevMan, Version 5.4.1, The Cochrane Collaboration, 2020). Pooled risk ratio (RR) was used for analysis, with P values less than 0.05 considered statistically significant. RESULTS: Twenty-four studies involving 2,579 patients were included in this analysis. The overall recurrence rates for patients treated with or without high-speed burring (HSB) are 11.9% (26/218) and 47.7% (92/193), respectively. The pooled RR for tumor recurrence is 0.33 (95% CI: 0.22 to 0.49, P<0.001). In the meanwhile, the overall recurrence rates for patients treated with or without chemical adjuvants are 23.5% (77/328) and 26.1% (73/280), respectively, with a pooled RR of 0.84 (95% CI: 0.63 to 1.10, P=0.89). Additionally, the overall recurrence rates for patients treated with or without polymethyl methacrylate (PMMA) are 20.4% (205/1,006) and 33.4% (314/939), respectively, with a pooled RR of 0.59 (95% CI: 0.50 to 0.69, P<0.001). CONCLUSIONS: Intraoperative application of HSB or PMMA has an additional antitumor effect, while the use of phenol or H2O2 fails to make any significant difference (PROSPERO: CRD42022344262).
Asunto(s)
Neoplasias Óseas , Legrado , Tumor Óseo de Células Gigantes , Humanos , Tumor Óseo de Células Gigantes/cirugía , Legrado/métodos , Neoplasias Óseas/cirugía , Neoplasias Óseas/patologíaRESUMEN
A case of a rapidly progressing giant cell tumor of the middle phalanx is presented. The patient underwent en bloc resection with iliac crest grafting and distal interphalangeal fusion. Surgical technique and patient's functional outcomes are described.
Asunto(s)
Neoplasias Óseas , Trasplante Óseo , Falanges de los Dedos de la Mano , Tumor Óseo de Células Gigantes , Ilion , Humanos , Ilion/trasplante , Tumor Óseo de Células Gigantes/cirugía , Neoplasias Óseas/cirugía , Falanges de los Dedos de la Mano/cirugía , Trasplante Óseo/métodos , Masculino , Artrodesis , Adulto , FemeninoRESUMEN
A man in his 30s came to our clinic with a year-long history of progressive pain and swelling in his knee. Diagnostic imaging revealed a displaced patellar fracture with an osteolytic, septated lesion and thinned expanded cortex in both fracture fragments. A core needle biopsy confirmed the diagnosis of giant cell tumour. Treatment involved wide excision of the tumour and the use of polypropylene mesh and a peroneal longus tendon autograft to reconstruct the extensor mechanism of the knee joint. One year postoperatively, the patient experienced no pain, demonstrated full range of motion and showed no signs of functional impairment or local tumour recurrence. This case highlights that reconstruction of the extensor mechanism of the knee after tumour excision with synthetic mesh is an affordable, user-friendly and widely accessible method. It can address large defects effectively while minimising the risks of disease transmission and graft lengthening, resulting in satisfactory outcomes.
Asunto(s)
Neoplasias Óseas , Rótula , Polipropilenos , Mallas Quirúrgicas , Humanos , Masculino , Rótula/cirugía , Rótula/lesiones , Rótula/diagnóstico por imagen , Neoplasias Óseas/cirugía , Neoplasias Óseas/complicaciones , Adulto , Tumor Óseo de Células Gigantes/cirugía , Fracturas Espontáneas/cirugía , Fracturas Espontáneas/etiología , Fracturas Espontáneas/diagnóstico por imagen , Procedimientos de Cirugía Plástica/métodos , Resultado del TratamientoRESUMEN
Giant cell tumour (GCT) accounts for 5% of all primary bone tumours. GCT in the distal third of ulna is quite rare. We present a case of recurrent GCT in distal third of ulna with malignant features involving tenosynovium. The case was treated by wide resection of tumour and on follow up, patient recovered well with no evidence of further recurrence. Considering the features, according to the literature reviewed, is the first case of its type.
Asunto(s)
Neoplasias Óseas , Tumor Óseo de Células Gigantes , Humanos , Tumor Óseo de Células Gigantes/diagnóstico por imagen , Tumor Óseo de Células Gigantes/cirugía , Tumor Óseo de Células Gigantes/patología , Cúbito/diagnóstico por imagen , Cúbito/cirugía , Neoplasias Óseas/diagnóstico por imagen , Neoplasias Óseas/cirugía , Neoplasias Óseas/patología , Extremidad Superior/patología , Recurrencia Local de Neoplasia/patologíaRESUMEN
BACKGROUND CONTEXT: Giant cell tumor (GCT) of bone is most commonly a benign but locally aggressive primary bone tumor. Spinal GCTs account for 2.7% to 6.5% of all GCTs in bone. En bloc resection, which is the preferred treatment for GCT of the spine, may not always be feasible due to the location, extent of the tumor, and/or the patient's comorbidities. Neoadjuvant denosumab has recently been shown to be effective in downstaging GCT, decreasing the size and extent of GCTs. However, the risk of neurologic deterioration is of major concern for patients with epidural spinal cord compression due to spinal GCT. We experienced this concern when a patient presented to our institution with a midthoracic spinal GCT with progressive epidural disease. The patient was not a good surgical candidate due to severe cardiac disease and uncontrolled diabetes. In considering nonoperative management for this patient, we asked ourselves the following question: What is the risk that this patient will develop neurologic deterioration if we do not urgently operate and opt to treat him with denosumab instead? PURPOSE: The purpose of this study was to assess the literature to (1) determine the risk of neurological deterioration in patients receiving neoadjuvant denosumab for the treatment of spinal GCT and (2) to evaluate the secondary outcomes including radiographic features, surgical/technical complexity, and histological features after treatment. STUDY DESIGN/SETTING: Meta-analysis of the literature. PATIENT SAMPLE: Surgical cases of spinal GCT that (1) presented with type III Campanacci lesions, (2) had epidural disease classified as Bilsky type 1B or above and (3) received neoadjuvant denosumab therapy. OUTCOME MEASURES: The primary outcome measure of interest was neurologic status during denosumab treatment. Secondary outcome measures of interest included radiographic features, surgical/technical complexity, histological features, tumor recurrence, and metastasis. METHODS: Using predetermined inclusion and exclusion criteria, PubMed and Embase electronic databases were searched in August 2022 for articles reporting spinal GCTs treated with neoadjuvant denosumab and surgery. Keywords used were "Spine" AND "Giant Cell Tumor" AND "Denosumab." RESULTS: A total of 428 articles were identified and screened. A total of 22 patients from 12 studies were included for review. 17 patients were female (17/22, 77%), mean age was 32 years (18-62 years) and average follow-up was 21 months. Most GCTs occurred in the thoracic and thoracolumbar spine (11 patients, 50%), followed by 36% in the lumbar spine and 14% in the cervical spine. Almost half of the patients had neurological deficits at presentation (10/22 patients, 45%), and more than 60% had Bilsky 2 or 3 epidural spinal cord compression. None of the patients deteriorated neurologically, irrespective of their neurological status at presentation (p-value=.02, CI -2.58 to -0.18). There were no local recurrences reported. One patient was found to have lung nodules postoperatively. More than 90% of cases had decreased overall tumor size and increased bone formation. Surgical dissection was facilitated in more than 85% of those who had documented surgical procedures. Four patients (18%) underwent initial spinal stabilization followed by neoadjuvant denosumab and then surgical excision of the GCT. Regarding the histologic analyses, denosumab eradicated the giant cells in 95% of cases. However, residual Receptor Activator of Nuclear Factor Kappa B Ligand (RANKL)-positive stromal cells were noted, in 27% (6 cases). CONCLUSIONS: Neoadjuvant denosumab was a safe and effective means of treating spinal GCTs prior to surgery. Neurologic status remained stable or improved in all cases included in our review, irrespective of the presenting neurologic status. The most appropriate dosage and duration of denosumab therapy is yet to be determined. We recommend future well-designed studies to further evaluate the use of neoadjuvant denosumab for patients with spinal GCT.
Asunto(s)
Denosumab , Tumor Óseo de Células Gigantes , Terapia Neoadyuvante , Neoplasias de la Columna Vertebral , Denosumab/uso terapéutico , Humanos , Neoplasias de la Columna Vertebral/tratamiento farmacológico , Neoplasias de la Columna Vertebral/cirugía , Tumor Óseo de Células Gigantes/tratamiento farmacológico , Tumor Óseo de Células Gigantes/patología , Tumor Óseo de Células Gigantes/cirugía , Conservadores de la Densidad Ósea/uso terapéutico , Compresión de la Médula Espinal/etiología , Compresión de la Médula Espinal/cirugía , Compresión de la Médula Espinal/tratamiento farmacológico , Adulto , Masculino , Femenino , Vértebras Torácicas/cirugía , Vértebras Torácicas/patología , Persona de Mediana EdadRESUMEN
BACKGROUND/AIM: Giant cell tumor of bone (GCTB) is a locally aggressive neoplasm that typically occurs in the ends (epiphyses) of long bones of young adults. Flat bones are uncommon sites of involvement. Herein, we describe an unusual case of pathologically proven GCT of the acromion. CASE REPORT: The patient was a 39-year-old woman with no history of trauma who presented with a 3-month history of right posterior shoulder pain. Physical examination revealed mild swelling and tenderness in the posterior aspect of the right shoulder. Plain radiograph showed a purely lytic lesion, suggestive of a bone tumor. Computed tomography demonstrated an intraosseous lytic lesion with associated cortical thinning and lack of periosteal reaction. On magnetic resonance imaging, the lesion exhibited slightly higher signal intensity compared to skeletal muscle on T1-weighted sequences and heterogeneous high signal intensity on T2-weighted sequences. Strong enhancement was observed following gadolinium administration. The lesion was treated by extensive curettage with adjuvant therapy comprising ethanol and the remaining cavity was filled with polymethylmethacrylate bone cement. Histologically, the lesion was composed of round or spindle-shaped mononuclear cells admixed with numerous osteoclast-like giant cells. Immunohistochemically, the mononuclear neoplastic cells were diffusely positive for H3.3 G34W. The patient was asymptomatic and there was no evidence of local recurrence or distant metastasis 5 months after surgery. CONCLUSION: Although rare, acromial GCTB should be considered in the differential diagnosis of posterior shoulder pain, especially in young and early middle-aged adults.
Asunto(s)
Neoplasias Óseas , Tumor Óseo de Células Gigantes , Femenino , Persona de Mediana Edad , Adulto Joven , Humanos , Adulto , Acromion/diagnóstico por imagen , Acromion/cirugía , Acromion/patología , Dolor de Hombro/diagnóstico , Dolor de Hombro/etiología , Tumor Óseo de Células Gigantes/cirugía , Tumor Óseo de Células Gigantes/diagnóstico por imagen , Neoplasias Óseas/diagnóstico por imagen , Neoplasias Óseas/patología , RadiografíaRESUMEN
Giant cell tumour of bone is a benign, locally aggressive osteolytic tumour that typically affects skeletally mature young individuals. It predominantly emerges within the metaphysis, extending towards the epiphysis of long bones, while occurrences in flat bones are exceptionally rare. We present a case of a woman in her late 20s who presented with a large right ischial mass. A biopsy confirmed the mass as a giant cell tumour. The tumour extended to the acetabulum, and due to the potential risk of significant bleeding and contamination during en bloc excision, a prudent approach involved initiating denosumab therapy, a monoclonal antibody targeting receptor activator of nuclear factor-κB ligand therapy, before proceeding with radical surgery. Denosumab therapy successfully rendered a previously inoperable tumour favourable for surgical intervention. We went on to perform a type 2 and 3 internal hemipelvectomy, followed by a reconstruction with a hip endoprosthesis replacement.
Asunto(s)
Conservadores de la Densidad Ósea , Neoplasias Óseas , Tumor Óseo de Células Gigantes , Neoplasias de la Columna Vertebral , Femenino , Humanos , Denosumab/uso terapéutico , Neoplasias Óseas/diagnóstico por imagen , Neoplasias Óseas/tratamiento farmacológico , Neoplasias Óseas/cirugía , Tumor Óseo de Células Gigantes/diagnóstico por imagen , Tumor Óseo de Células Gigantes/tratamiento farmacológico , Tumor Óseo de Células Gigantes/cirugía , Conservadores de la Densidad Ósea/uso terapéutico , Neoplasias de la Columna Vertebral/patología , BiopsiaRESUMEN
RESUMEN Introducción: Los tumores de células gigantes pueden originarse en el tejido óseo, sinovial o cualquier otro tejido blando. Se caracterizan por su rápido crecimiento. A pesar de ser comúnmente benignos, si se dejan evolucionar sin tratamiento, hay riesgo de que en su proceso de crecimiento destruyan el tejido adyacente y afecten la funcionalidad, estructura y apariencia de la zona anatómica afectada. Objetivo: Describir el curso clínico y manejo terapéutico de un paciente con tumor de células gigantes en el antebrazo. Caso clínico: Se presenta paciente masculino de 28 años, que se le diagnosticó tumoración ósea en tercio distal del cúbito, y a quien, por su voluntad de no atenderse, no se le realizó el abordaje y manejo quirúrgico. Un año después, regresó al servicio de urgencias. Tenía mayor volumen en las dimensiones tumorales, con cambios a nivel del tercio distal del cúbito, lesiones de patrón lítico, pérdida de la cortical, con reacción perióstica, bordes mal definidos y afectación de tejidos blandos circundantes. Se diagnóstico probable tumor de células gigantes. El manejo quirúrgico permitió la conservación del antebrazo, pero a un año de su intervención quirúrgica, dada la probabilidad de recidiva, su pronóstico permanece incierto. Conclusiones: La velocidad de crecimiento de los tumores de células gigantes amerita decisiones oportunas, dado que el tiempo que transcurre previo al tratamiento puede, como en el presente caso, traducirse en un crecimiento destructivo de los tejidos adyacentes. A más de un año de la cirugía, el pronóstico del paciente es incierto, pues la probabilidad de recidiva permanece latente(AU)
ABSTRACT Introduction: Giant cell tumors can originate in bone, synovial, or any other soft tissue. They are characterized by their rapid growth. Despite being commonly benign, if they are allowed to evolve without treatment, they may destroy adjacent tissue, in its growth process, affecting the functionality, structure and appearance of the affected anatomical area. Objective: To describe the clinical course and therapeutic management of a patient with a giant cell tumor in the forearm. Clinical case: We report the case of a 28-year-old male patient, who was diagnosed with a bone mass in the distal third of the ulna. This patient desired not to undergo surgical management. A year later, he returned to the emergency room. the tumor had greater dimensions, changes at the level of the distal third of ulna, lytic pattern lesions, loss of the cortex, periosteal reaction, poorly defined edges and involvement of surrounding soft tissues. Giant cell tumor was the probable diagnosis. Surgical management allowed the forearm preservation, but one year after surgery, the prognosis remains uncertain, given the probability of recurrence. Conclusions: The growth rate of giant cell tumors merits timely decisions, since the time that elapses prior to treatment can, as in the present case, translate into destructive growth of adjacent tissues. More than a year after surgery, the prognosis is uncertain for this patient, as the probability of recurrence remains latent(AU)
RÉSUMÉ Introduction: Les tumeurs à cellules géantes peuvent être localisées au niveau du tissu osseux, du tissu synovial ou d'un autre tissu mou quelconque. Elles sont caractérisées par une croissance rapide. Malgré leur classique bénignité, si elles évoluent sans traitement, elles risquent de détruire le tissu adjacent et d'altérer la fonction, la structure et l'apparence de la région affectée lors du processus de croissance. Objectif: Décrire l'évolution clinique et la prise en charge thérapeutique d'un patient atteint de tumeur à cellules géantes au niveau de l'avant-bras. Cas clinique: Un patient âgé de 28 ans, diagnostiqué d'une tumeur osseuse au niveau du tiers distal du cubitus, sans abord ni traitement chirurgical dû à son refus de soin, est présenté. Un an après, il est rentré au service d'urgence. La tumeur avait grandi, et présentait des changements au niveau du tiers distal du cubitus, des lésions lytiques, une perte osseuse corticale, une réaction périostée, des bords mal définis, et un dommage des tissus mous environnants. Une probable tumeur à cellules géantes a été diagnostiquée. Le traitement chirurgical a permis la conservation de l'avant-bras, mais un an après l'intervention, son pronostic reste incertain, étant donnée la probabilité de récidive. Conclusions: La rapide croissance des tumeurs exige des décisions opportunes, car le temps parcouru avant le traitement peut se traduire -comme dans ce cas- par une atteinte destructive des tissus adjacents. Plus d'un an après la chirurgie, le pronostic du patient reste incertain, parce que la probabilité de récidive est encore latente(AU)
Asunto(s)
Humanos , Masculino , Adulto , Cúbito/cirugía , Neoplasias Óseas/cirugía , Neoplasias Postraumáticas/cirugía , Tumor Óseo de Células Gigantes/cirugía , México , Recurrencia Local de Neoplasia/diagnósticoRESUMEN
RESUMEN El tumor de células gigantes se define como un tumor óseo benigno que invade las partes blandas localmente de forma agresiva. Se presenta una paciente con un tumor de células gigantes recidivante en el tercio distal del radio derecho, con signos de necrosis superficial e infección sobreañadidos, la cual, dada la magnitud y severidad de la lesión, requirió una amputación supracondílea de la extremidad. Presentó una evolución postoperatoria favorable, con recuperación física y psicológica(AU)
ABSTRACT Giant cell tumor is defined as a benign bone tumor that aggressively invades soft tissue locally. We present a patient with a recurrent giant cell tumor in the distal third of the right radius, showing signs of superimposed necrosis and infection, which, given the injury magnitude and severity, required supracondylar amputation of the limb. Her postoperative evolution was favorable, and this patient underwent physical and psychological recovery(AU)
RÉSUMÉ La tumeur à cellules géantes est définie comme une tumeur osseuse bénigne qui envahit agressivement les parties molles locales. Une patiente atteinte de tumeur récidivante à cellules géantes au niveau du tiers distal du radius droit, avec signes de nécrose superficielle et d'infection surajoutés, laquelle a requis une amputation supracondylienne du membre, due à la magnitude et à la sévérité de la lésion, est présentée. Elle a montré une évolution postopératoire favorable, avec une bonne récupération physique et psychologique.
Asunto(s)
Humanos , Femenino , Adulto , Radio (Anatomía)/cirugía , Neoplasias Óseas/cirugía , Tumor Óseo de Células Gigantes/cirugía , Amputación Quirúrgica/métodosRESUMEN
ABSTRACT Peri-articular giant cell tumours present a unique challenge to the orthopaedic surgeon due to their locally aggressive nature. Native joint-preserving options confer less morbidity in comparison to radical excision and reconstruction; however, recurrence rates tend to be higher. The use of polymethyl methacryllate (PMMA) decreases the recurrence rate, but it has potentially devastating effects on the articular cartilage. To safeguard against this, the use of an insulating layer between the PMMA and the articular cartilage may be utilized with the goal of protecting the latter and is referred to as the Sandwich technique.
RESUMEN Los tumores de células gigantes periarticulares representan un desafío único al cirujano ortopédico debido a su naturaleza localmente agresiva. Las opciones de conservación de las articulaciones nativas confieren menos morbilidad en comparación con la supresión y reconstrucción radicales. Sin embargo, las tasas de recurrencia tienden a ser más altas. El uso de polimetilmetacrilato (PMMA) disminuye la tasa de recurrencia, pero tiene efectos potencialmente devastadores sobre el cartílago articular. Para protegerlo, el uso de una capa aislante entre el PMMA y el cartílago articular puede ser utilizarse con el objetivo de proteger este último, lo que se conoce como la técnica del sándwich.
Asunto(s)
Humanos , Masculino , Adolescente , Neoplasias Óseas/cirugía , Tumor Óseo de Células Gigantes/cirugía , Polimetil Metacrilato/administración & dosificación , Articulación de la Rodilla , Neoplasias Óseas/diagnóstico por imagen , Resultado del Tratamiento , Tumor Óseo de Células Gigantes/diagnóstico por imagen , Recuperación del MiembroRESUMEN
Abstract: The giant cell tumor of bone is one of the most controversial neoplasms due to growth patterns that may present. The case reported shows a very aggressive tumor in a classic location, but key to hand function. Rather than treat with radical surgery, was planned and performed a wide resection with an ulnar-carpus arthrodesis and microsurgical reconstruction of the defect throught an anterolateral thigh flap. The multidisciplinary approach of bone neoplasms produce a positive impact on patients.
Resumen: El tumor óseo de células gigantes es una de las neoplasias más controversiales debido a los patrones de crecimiento que pueden presentar. El caso reportado muestra un tumor muy agresivo en una localización clásica, pero clave para la función de la mano. En lugar de tratarla mediante cirugía radical, se planeó y realizó una resección amplia con artrodesis cúbito-carpiana y la reconstrucción microquirúrgica del defecto mediante un colgajo anterolateral de muslo. El abordaje multidisciplinario de las neoplasias óseas repercute positivamente en los pacientes.
Asunto(s)
Humanos , Radio (Anatomía)/cirugía , Neoplasias Óseas/cirugía , Tumor Óseo de Células Gigantes/cirugía , Artrodesis , Articulación de la Muñeca , Resultado del Tratamiento , Recuperación del Miembro , MicrocirugiaRESUMEN
Resumen: Introducción: El tumor de células gigantes es una neoplasia agresiva, representa aproximadamente entre 5 y 8.6% de los tumores óseos primarios. Más de 50% afecta la rodilla, pero puede afectar la totalidad de los huesos. Objetivo: Se exponen ocho casos candidatos a amputación a los que se propuso reemplazo articular como una alternativa de salvamento. Material y métodos: Se presentan ocho casos diagnosticados histopatológicamente en cadera y rodilla candidatos a amputación referidos por otros servicios. Se realizó resección en bloque y reemplazo articular de tipo tumoral de rodilla y cadera. Resultados: La evolución clínica y radiológica fue satisfactoria, se obtuvo buen resultado en los ocho casos sin complicaciones transoperatorias y postoperatorias, siendo lo más importante el salvamento de la extremidad pélvica con una mejor calidad de vida. Se muestran los resultados funcionales de las prótesis. Discusión: Son casos de salvamento de la extremidad con tumores destructivos en los que se evita la amputación con una recuperación de su vida normal en 80%.
Abstract: Introduction: The giant-cell tumor is an aggressive neoplasia, represents approximately from the 5 the 8.6% of primary bone tumors; more of 50% affects the pelvic extremity, being able to affect the totality of the bones. Objective: To present the case series of tumors around the knee and hip that we offered a tumoral joint replacement as an alternative to amputation. Material and methods: We present eight cases of extensive giant cells tumors, we did en bloc resection and tumoral joint replacement. Results: The clinical and radiological evolution was satisfactory, without postoperative complications and the most important, avoided an amputation with a better quality of life. Discussion: Alternative reconstructive treatment option with a recovery to its normal life in a 80% and a low index of complications.
Asunto(s)
Humanos , Neoplasias Óseas/cirugía , Tumor Óseo de Células Gigantes/cirugía , Artroplastia de Reemplazo , Calidad de Vida , Resultado del Tratamiento , Articulación de la RodillaRESUMEN
El tumor óseo de células gigantes (TOCG) es un tumor óseo primario que se presenta con más frecuencia en la tercera edad de la vida, ubicándose principalmente a nivel del fémur distal. El desarrollo de una biopsia para su establecer su diagnóstico y poder comenzar con rapidez el tratamiento adecuado, constituye un procedimiento fundamental para poder establecer la resección quirúrgica lo más temprano posible. En este artículo se presenta un caso de TOCG en una paciente de 30 años. Se discute su etiopatogenia, signos y síntomas, diagnóstico, como así también los procedimientos diagnóstico y terapeútico adecuados para lograr una resolución positiva de esta patología.
The giant cell tumor of bone (OCD) is a primary bone tumor that occurs most frequently in the third age of life, being located mainly at the distal femur. The development of a biopsy to establish the diagnosis and to begin appropriate treatment quickly is a fundamental to establish as early as possible surgical resection procedure. In this article a case of TOCG is presented in a patient of 30 years. Its etiology, signs and symptoms, diagnosis, as well as an adequate diagnostic and therapeutic procedures to achieve a positive resolution of this pathology is discussed.